Alzamend Neuro, Inc. (ALZN) [Rocket]

In millions, except per share items	Apr-30-23	Apr-30-22	Apr-30-21	Apr-30-20	Apr-30-19
	10-K	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.0	0.0	0.0	3.7
Revenue growth				-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	5.0
Gross profit	0.0	0.0	0.0	0.0	-1.3
Gross margin					-35.4%
Selling, general and administrative [+]	7.4	7.1	3.6	3.4	1.3
General and administrative	7.4	7.1	3.6	3.4	1.3
Research and development	7.4	5.2	1.3	1.1
Other operating expenses					2.4
EBITDA [+]	-14.8	-12.3
EBITDA growth	20.6%	148.7%	11.9%	-11.7%
EBITDA margin					-135.4%
Depreciation and amortization	0.0	0.0
EBIT [+]	-14.9	-12.3	-5.0	-4.4	-5.0
EBIT growth	20.7%	148.8%	11.9%	-11.7%
EBIT margin					-135.4%
Interest expense, net [+]	0.0	0.0	0.1	0.0
Interest expense	0.0	0.0	0.1
Interest income				0.0
Other income (expense), net [+]		0.0	0.0		0.1
Gain (loss) on debt retirement		0.0	0.1
Pre-tax income	-14.9	-12.4	-5.0	-4.4	-4.9
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-14.9	-12.4	-5.0	-4.4	-4.9
Net margin					-131.4%

Basic EPS [+]	($0.15)	($0.14)	($0.07)	($0.06)	($0.08)
Growth	10.0%	99.7%	12.2%	-25.1%
Diluted EPS [+]	($0.15)	($0.14)	($0.07)	($0.06)	($0.08)
Growth	10.0%	99.7%	12.2%	-25.1%

Shares outstanding (basic) [+]	97.5	89.1	72.7	71.3	58.8
Growth	9.5%	22.6%	2.0%	21.1%
Shares outstanding (diluted) [+]	97.5	89.1	72.7	71.3	58.8
Growth	9.5%	22.6%	2.0%	21.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.